C80.0: Disseminated malignant neoplasm, unspecified
C80.0 is a billable, specific ICD-10-CM code for disseminated malignant neoplasm, unspecified. It is valid for submission on a claim.
Check C80.0 with the rest of the claim: free scrubberInclusion terms
Alternative wordings a physician may use in the chart for this same code.
- Carcinomatosis NOS
- Generalized cancer, unspecified site (primary) (secondary)
- Generalized malignancy, unspecified site (primary) (secondary)
Excludes1 inherited from the categories above C80.0
A category’s note binds every code beneath it.
Written on C80: Malignant neoplasm without specification of site
- malignant carcinoid tumor of unspecified site (C7A.00)
- malignant neoplasm of specified multiple sites- code to each site
Other codes that can never be billed with C80.0
Their own Excludes1 notes name this code, so the conflict is not listed above.
- C79.9Secondary malignant neoplasm of unspecified site
Risk adjustment
C80.0 risk-adjusts. Under the CMS-HCC V28 model it maps to this category:
- HCC 18 Cancer Metastatic to Bone, Other and Unspecified Metastatic Cancer; Acute Leukemia Except Myeloid2.341 RAF
Coefficient shown for the Community Non-dual Aged segment. A higher HCC in the same hierarchy will suppress this one, so capturing it does not always add score. Look up the whole chart to see which of its HCCs the hierarchy would zero.
Medicare coverage
C80.0 is named in 51 Medicare coverage policies: 51 listing it as supporting medical necessity. Which one applies depends on your Medicare contractor.
- A52450Billing and Coding: Paclitaxel (e.g., Taxol®/Abraxane ™)
- A52479Oral Anticancer Drugs - Policy Article
- A52480Oral Antiemetic Drugs (Replacement for Intravenous Antiemetics) - Policy Article
- A52986Billing and Coding: Biomarkers for Oncology
Alphabetic index entries that lead here
- Carcinomatosis
- Carcinoma›generalized, with unspecified primary site
- Carcinomatosis›unspecified site(primary) (secondary)
Code history
Unchanged in every release from FY2024 to FY2027.